A detailed history of Glenmede Trust CO Na transactions in Incyte Corp stock. As of the latest transaction made, Glenmede Trust CO Na holds 697,025 shares of INCY stock, worth $48.7 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares
697,025
Previous 853,987 18.38%
Holding current value
$48.7 Million
Previous $51.8 Million 11.0%
% of portfolio
0.22%
Previous 0.26%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$57.33 - $68.61 $9 Million - $10.8 Million
-156,962 Reduced 18.38%
697,025 $46.1 Million
Q2 2024

Aug 14, 2024

BUY
$51.18 - $63.75 $43.7 Million - $54.4 Million
853,987 New
853,987 $51.8 Million
Q4 2020

Feb 16, 2021

SELL
$80.74 - $97.7 $101,409 - $122,711
-1,256 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$85.07 - $109.69 $7,060 - $9,104
83 Added 7.08%
1,256 $112,000
Q2 2020

Aug 14, 2020

BUY
$74.18 - $108.93 $17,061 - $25,053
230 Added 24.39%
1,173 $121,000
Q4 2019

Feb 12, 2020

SELL
$73.04 - $95.72 $20,378 - $26,705
-279 Reduced 22.83%
943 $82,000
Q2 2019

Aug 13, 2019

BUY
$73.52 - $88.7 $12,498 - $15,079
170 Added 16.16%
1,222 $103,000
Q1 2019

May 14, 2019

BUY
$63.56 - $88.17 $24,979 - $34,650
393 Added 59.64%
1,052 $89,000
Q4 2018

Feb 14, 2019

BUY
$58.5 - $69.94 $38,551 - $46,090
659 New
659 $41,000
Q3 2018

Nov 15, 2018

SELL
$61.75 - $74.23 $30,936 - $37,189
-501 Closed
0 $0
Q2 2018

Aug 15, 2018

BUY
$60.85 - $83.98 $1,460 - $2,015
24 Added 5.03%
501 $34,000
Q4 2017

Feb 15, 2018

SELL
$93.56 - $116.6 $19,647 - $24,486
-210 Reduced 30.57%
477 $45,000
Q3 2017

Nov 14, 2017

BUY
$109.15 - $138.27 $74,986 - $94,991
687
687 $0

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15.6B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Glenmede Trust CO Na Portfolio

Follow Glenmede Trust CO Na and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Glenmede Trust CO Na, based on Form 13F filings with the SEC.

News

Stay updated on Glenmede Trust CO Na with notifications on news.